In a phase 1 trial (5 people with mild Alzheimer), dasatinib reached the cerebrospinal fluid but quercetin did not; tolerance was acceptable. ConfidenceEstablished Level of evidence●●●●●○ Randomized clinical trial Observed inHuman MissionMap of aging (12 hallmarks) ConceptsCellular senescenceDasatinib + quercetin (D+Q)Alzheimer's disease